SRRK | tickerfilter.com

Fundamental analysis

22%

Profitability 25%

Dept financing 12%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-4.40%

1 Month

9.48%

3 Months

3.80%

6 Months

69.68%

1 Year

60.35%

2 Year

241.43%

Key data

Stock price

$47.80

P/E Ratio

N/A

DAY RANGE

$47.70 - $49.69

EPS

-$3.29

52 WEEK RANGE

$27.07 - $51.62

52 WEEK CHANGE

$51.07

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

114.883 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-07-2025

BETA

3.33

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,738,587

AVERAGE 30 VOLUME

$1,786,584

Company detail

CEO: Jay T. Backstrom
Region: US
Website: scholarrock.com
Employees: 140
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Scholar Rock Holding Corporation focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin, and SRK-181, which is in Phase 1 clinical trials. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients.

SRRK - Scholar Rock Holding Corp